Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02116530 |
Recruitment Status :
Completed
First Posted : April 17, 2014
Results First Posted : April 10, 2017
Last Update Posted : May 7, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hematopoietic/Lymphoid Cancer Nausea and Vomiting Unspecified Adult Solid Tumor, Protocol Specific | Drug: Olanzapine Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin) Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant) Other: Placebo | Phase 3 |
Patients with cancer may receive chemotherapy that may cause nausea and vomiting. The purpose of this study is to determine if the use of olanzapine in combination with antiemetic therapy can significantly reduce nausea and vomiting in a large number of patients receiving chemotherapy. Patients are randomized to one of two treatment arms. Please see the "Arms and Intervention" sections for more detailed information. The primary objective is to compare the number of patients with no nausea for the acute (0-24 hours post-chemotherapy), delayed (24-120 hours post-chemotherapy) and overall periods (0-120 hours post-chemotherapy) for patients receiving HEC. The secondary objectives are:
- To compare the complete response (CR) (no emetic episodes and no use of rescue medication) in the acute, delayed and overall periods
- To compare the incidences of potential toxicities ascribed to olanzapine
Protocol treatment is to begin ≤ 14 days of registration. Patients will receive treatment on Days 1-4. Patients will be permitted to take rescue therapy of the treating investigator's choice for nausea and/or emesis/retching, based on clinical circumstances. After completing treatment, patients will be monitored for side effects.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 401 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Supportive Care |
Official Title: | Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC): A Randomized, Double-Blind, Placebo-Controlled Trial |
Study Start Date : | August 2014 |
Actual Primary Completion Date : | April 2015 |
Actual Study Completion Date : | November 2015 |
Arm | Intervention/treatment |
---|---|
Experimental: Olanzapine + Chemotherapy + Antiemetic treatment
Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as the following anti-nausea/vomiting drugs:
|
Drug: Olanzapine
oral Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin) oral or IV Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant) oral or IV |
Active Comparator: Placebo + Chemotherapy + Antiemetic treatment
Patients will receive the chemotherapy drugs cisplatin or cyclophosphamide and doxorubicin as well as usual anti-nausea/vomiting drugs:
|
Drug: Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)
oral or IV Drug: Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant) oral or IV Other: Placebo oral |
- Proportion of Patients With no Nausea [ Time Frame: 0 to 120 hours after chemotherapy ]No nausea was defined as a response of 0 in the nausea item of Nausea and Vomiting Daily Diary/Questionnaire in the acute (0-24 hours), delayed (25-120 hours) and overall (0-120 hours) periods after chemotherapy.
- Median Nausea Scores [ Time Frame: Baseline and Day 2 to Day 6 after chemotherapy ]Nausea scores was measured using a visual-analogue scale ranging from 0 (none) to 10 (as bad as it can be).
- Proportion of Patients With Complete Response [ Time Frame: 0 to 120 hours after chemotherapy ]Complete response was defined as no emetic episodes and no use of rescue medication during the acute (0-24 hours), delayed (25-120 hours) and overall (0-120 hours) periods as measured by the Nausea and Vomiting Daily Diary/Questionnaire.
- Mean Scores of Potential Toxicities Related to Olanzapine as Measured by the Nausea and Vomiting Daily Diary/Questionnaire [ Time Frame: Baseline and day 2 to 6 days after chemotherapy ]Patients were asked to record daily levels of undesired sedation and appetite increase using a visual-analogue scale ranging from 0 (none) to 10 (as bad as it can be).
- Frequency of Rescue Medication [ Time Frame: Day 2 to Day 6 after chemotherapy ]Patients were asked to record daily number of extra nausea/vomiting pills taken because they developed nausea/vomiting in the following categories: None, One, Two, More than two in Nausea and Vomiting Daily Diary Questionnaire.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
- Diagnosis of malignant disease
-
No prior chemotherapy and scheduled to receive HEC (either cisplatin-containing regimen or anthracycline + cyclophosphamide [AC])
- Cisplatin at a dose of ≥70mg/m^2, with or without other chemotherapy agent(s) OR
- Anthracycline (60 mg/m^2) plus cyclophosphamide(600 mg/m^2)
- Age ≥18 years
- Eastern Cooperative Oncology Group (ECOG) Performance Status 0, 1 or 2
-
Required Initial Laboratory Values ≤ 120 days prior to registration
- Serum Creatinine ≤2.0 mg/dL
- Serum glutamic oxaloacetic transaminase (SGOT) or Serum glutamic oxaloacetic transaminase (SGPT) ≤3 x Upper Limit of Normal (ULN)
- Absolute neutrophil count (ANC) ≥1500/mm^3
- No nausea or vomiting ≤ 24 hours prior to registration
- Negative pregnancy test (serum or urine) done ≤7 days prior to registration, for women of childbearing potential only (per clinician discretion)
- No severe cognitive compromise
- No known history of CNS disease (e.g. brain metastases, seizure disorder)
- No treatment with another antipsychotic agent such as risperidone, quetiapine, clozapine, phenothiazine or butyrophenone ≤30 days prior to registration or planned during protocol therapy
- No chronic phenothiazine administration as an antipsychotic agent (patients may receive prochlorperazine and other phenothiazines as rescue anti-emetic therapy)
- No concurrent use of amifostine
- No concurrent abdominal radiotherapy
- No concurrent use of quinolone antibiotic therapy
- No chronic alcoholism (as determined by the investigator)
- No known hypersensitivity to olanzapine
- No known cardiac arrhythmia, uncontrolled congestive heart failure or acute myocardial infarction within the previous six months.
- No history of uncontrolled diabetes mellitus (e.g. on insulin or an oral hypoglycemic agent)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02116530
Study Chair: | Rudolph M. Navari, MD, PhD, FACP | Indiana University School of Medicine South Bend |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Alliance for Clinical Trials in Oncology |
ClinicalTrials.gov Identifier: | NCT02116530 |
Other Study ID Numbers: |
A221301 NCI-2014-00446 ( Other Identifier: NCI Clinical Trial Reporting Program ) U10CA031946 ( U.S. NIH Grant/Contract ) |
First Posted: | April 17, 2014 Key Record Dates |
Results First Posted: | April 10, 2017 |
Last Update Posted: | May 7, 2020 |
Last Verified: | April 2020 |
Nausea Vomiting Signs and Symptoms, Digestive Dexamethasone Cyclophosphamide Doxorubicin Ondansetron Olanzapine Aprepitant Fosaprepitant Palonosetron Granisetron Antiemetics Immunosuppressive Agents Immunologic Factors |
Physiological Effects of Drugs Antirheumatic Agents Antineoplastic Agents, Alkylating Alkylating Agents Molecular Mechanisms of Pharmacological Action Antineoplastic Agents Myeloablative Agonists Anti-Inflammatory Agents Autonomic Agents Peripheral Nervous System Agents Gastrointestinal Agents Glucocorticoids Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Antineoplastic Agents, Hormonal |